November 20, 2017. By Anne Wallace.
Trenton, NJ: The FDA warns of fracture risk with Invokana and Invokamet and more recently of a higher risk for foot and leg amputation. The lawsuit chickens have now come home to roost.Read [ Invokana Lawsuits Consolidated into MDL in New Jersey ]
August 22, 2017. By Gordon Gibb.
Los Angeles, CA: When Janumet (sitagliptin and metformin combined) was approved by the US Food and Drug Administration (FDA) in 2007, the type 2 diabetes drug was within five years of achieving sales of $1.7 Billion. That year, when Janumet hit blockbuster status by 2012, the parent drug of Janumet – Januvia – earned $4 Billion for manufacturer Merck & Co. Januvia has been associated with Januvia side effects, and has resulted in Januvia cancer lawsuits.Read [ Janumet Patient Felled by Cancer of the Pancreas in 2012 ]
June 24, 2017. By Brenda Craig.
Philadelphia, PA Final results from two independent clinical trials indicate the amputation risk for users of the Type 2 Diabetes drug Canagliflozin, marketed as Invokana, Invokamet, Invokamet XR, are much greater than previously understood.Read [ FDA Black Box Warning Adds Fuel to Invokana Lawsuits ]
June 22, 2015. By Jane Mundy.
Read [ Januvia’s (Almost) Clean Bill of Health Not Ruling Out Januvia Pancreatitis ]
April 1, 2015. By Jane Mundy.
Read [ “Januvia Killed My Husband” ]
February 3, 2015. By Jane Mundy.
Read [ Januvia “A Killer” ]
January 4, 2015. By Jane Mundy.
Read [ Pharmacist Warns Patient about Januvia ]
December 2, 2014. By Jane Mundy.
Read [ Januvia Cancer and Complaints on the Rise ]
November 7, 2014. By Jane Mundy.
Read [ Januvia Damage Done ]
October 6, 2014. By Jane Mundy.
Read [ Januvia Lawsuits Moving Forward, Reviews Ongoing ]